Uncertain Future for Skinny Labels as Federal Circuit Panel Agrees to Rehearing
Litigation on Amgen’s Biosimilar to Avastin Settles on Heels of Amgen Procedural Victory at Federal Circuit
Uptick in PTAB Motions to Amend Demonstrate Increasing Importance of this Strategy
2019 Ends and 2020 Begins with a Flurry of Biosimilar Activity in East Asian Markets
Presence of Harm Central to Real Party-in-Interest Issues in PTAB Precedential Decisions
Claims of Genentech’s Carter ’213 Patent Found Unpatentable
Federal Circuit Confirms that New Evidence Before PTAB Sinks Claims that Survived ITC Action
First IPR Against Biogen’s ’172 Patent Instituted After Multiple Attempts
